Company / Cash & Equivalents
GRAIL, Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$249.7M
FY2025
5-year range
$97.3M / $249.7M
FY2022-FY2025
Trend
+16.6%
vs FY2024
Sector context
#71 of 148
Health Care
What the data says
At $250M, GRAIL, Inc.'s cash & equivalents ranks #71 of 148 in the Health Care sector. Improved from $97M to $250M over the past 2 years.
Based on SEC 10-K filings.
$250M in FY2025 with a 3-year CAGR of +1.1%.
Improved from $97M to $250M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +1.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#71 of 148 in Health CareTop 48% of 148This company $249.7M Sector average $1.2B
▼
-78.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +1.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 16.6% year-over-year.
- Ranks #71 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $249.7M | +16.6% |
| FY2024 | $214.2M | +120.2% |
| FY2023 | $97.3M | -59.7% |
| FY2022 | $241.6M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026